Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Our Mission - To enhance the practice of lipid management in clinical medicine. Consistent with the mission statement, the National Lipid Association's goals are diversity, inclusion, equality, professionalism, public service, multidisciplinary approach, continuous growth and development, business ethics, cooperation.

Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases. Along with the commercial approval of TEGSEDI® in the U.S., E.U., Canada and Brazil, and WAYLIVRA® in the E.U., Akcea is advancing a mature pipeline of novel medicines which were discovered by Ionis and are based on Ionis' proprietary antisense technology.

More than 1 in 200 people have an inherited cardiovascular condition. Ambry Genetics®' mission is to provide the most advanced genetic testing information available to help you identity those at risk to inform personalized management options. If we know a patient has a disease-causing genetic change, it not only informs disease management for that patient, but also indicates that we can test others in the family and provide them with potentially life-saving information.

Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.

Esperion Therapeutics, Inc. is a pharmaceutical company passionately committed to developing and commercializing non-statin, once-daily, oral therapies to lower elevated low-density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies.

LIPOSORBER® is a lipoprotein apheresis therapeutic system used to remove acutely atherogenic cholesterol factors (LDL cholesterol, triglycerides, and Lp(a)) from the blood. LIPOSORBER® is indicated for functional hypercholesterolemia patients with an LDL-C ≥ 100 mg/dl and/or Lp(a) ≥ 60 mg/dl with either established coronary artery disease (CAD) or peripheral arterial disease (PAD) whom failed to achieve the recommended therapeutic targets by using maximum tolerable lipid-lowering drug therapies and diet.

MotherToBaby is the nation's leading authority and most trusted source of evidence-based information on the safety of medications and other exposures during pregnancy and while breastfeeding. We are currently conducting a pregnancy registry on Repatha® (evolocumab) while also evaluating the effects of familial hypercholesterolemia (FH) and atherosclerotic cardiovascular disease (ASCVD) during pregnancy. If you have a patient who is currently pregnant and taking Repatha® or is managing FH or ASCVD, refer her today!

ZypitamagTM (pitavastatin) tablets is a pharmaceutical alternative to Livalo. Zypitamag is covered in over 150 million lives and is available to most patients at near generic pricing. Through our savings program, eligible patients will receive the first 30-days of Zypitamag free followed by a $10/month co-pay. If patients are uninsured, or wish to pay cash for their prescription, Zypitamag is available at a price of $29 per month for a 90-day prescription. Eligibility criteria apply.

The mission of the National Lipid Association is to enhance lipid management in clinical medicine. We do so through activities that focus on science, clinical care, and public advocacy. The NLA has a professionally diverse membership and leadership, and continues to work towards greater diversity, inclusion, and equality within all aspects of the organization. The NLA pledges to further advance our diversity, inclusion, and equality commitment though the following actions: Affirming diversity, inclusion, and equality as a core value in all aspects of our mission and developing a structure to focus efforts to promote: Diversity within our organization, inclusion of social determinants of health and gaps in knowledge related to lipid management in the scientific literature, and to ensure this issue is included in our educational offerings.

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing and commercializing therapeutics to cost-effectively improve cardiovascular health. Amarin's lead product, VASCEPA® (icosapent ethyl), is available by prescription in certain countries, including in the United States. For more information about Amarin, visit www.amarincorp.com. For more information about VASCEPA, visit www.vascepa.com.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.